Morinaga Milk Industry Co., Ltd. (2264.T)
| Previous Close | 3,368.00 |
| Open | 3,369.00 |
| Bid | 3,364.00 x 0 |
| Ask | 3,373.00 x 0 |
| Day's Range | 3,340.00 - 3,398.00 |
| 52 Week Range | 2,295.00 - 3,530.00 |
| Volume | |
| Avg. Volume | 280,019 |
| Market Cap | 291.192B |
| Beta (5Y Monthly) | 0.07 |
| PE Ratio (TTM) | 4.84 |
| EPS (TTM) | 696.11 |
| Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | 90.00 (2.67%) |
| Ex-Dividend Date | Sept 27, 2024 |
| 1y Target Est | 3,498.00 |
Business WireMorinaga Milk’s New Research Breakthrough Backed the Superiority of its Human-Residential Bifidobacteria (HRB) Strains in Metabolizing Toxin Precursor in the Gut
TOKYO, May 30, 2024--Groundbreaking discovery: HRB species convert harmful indole into beneficial indole-3-lactic acid, highlighting the superiority of HRB as probiotics.
Business WireMorinaga Milk’s Probiotic Bifidobacterium breve B-3 Receives Approval of Individual Recognized Registration in South Korea
TOKYO, November 17, 2023--Morinaga Milk's Bifidobacterium breve B-3 received Individually Recognized approval in South Korea for its clinical efficacy on body fat reduction.
Business WireMorinaga Milk's Probiotic Bifidobacterium longum subsp. longum BB536 Receives ANVISA Approval with Gut Health Functional Claim in Brazil
TOKYO, September 07, 2023--Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, is pleased to announce that its proprietary probiotic strain Bifidobacterium longum subsp. longum BB536 (hereafter referred to as Bifidobacterium longum BB536) has obtained approval from the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, ANVISA). This approval, granted on July 27, 2023, allows for the utilization of Bifidobacterium longum BB536 in die
